This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Academic Highlights

Like a Game of Chess, Every Move Matters: The Role of Antibodies in the Myasthenia Gravis Treatment Landscape

Vera Bril, MD, FRCPCa; Nicholas J. Silvestri, MD, FAANb; and Carolina Barnett-Tapia, MD, PhDa

Published: October 27, 2022


Symptoms and disease pathophysiology of myasthenia gravis (MG) vary considerably with each patient, and their individual preferences and priorities add to the need for individualized treatment of this autoimmune disease. Research in MG has grown substantially in recent years. New treatments have the potential of being both effective and well tolerated, addressing the trade-off of choosing either efficacy or tolerability when selecting treatments. Promising investigational treatments that may become available in the future may allow more patients than ever before to achieve an asymptomatic state, with the ultimate goal being to turn off abnormal antibody production.

PDF version of article
Note: To read the entire article and receive credit, you must navigate through the entire online activity. Click link below.


Prim Care Companion CNS Disord 2022;24(6):AR21018AH3C

To cite: Bril V, Silvestri NJ, Barnett-Tapia C. Like a game of chess, every move matters: the role of antibodies in the myasthenia gravis treatment landscape. Prim Care Companion CNS Disord. 2022;24(6):AR21018AH3C.
To share:
© 2022 Physicians Postgraduate Press, Inc.

aDivision of Neurology, University of Toronto and University Health Network
bUniversity at Buffalo Jacobs School of Medicine and Biosciences, New York

Volume: 24

Quick Links: